首页> 外文期刊>Nature biotechnology >Recent DBT-BIRAC intiatives postured to boost India's biotech industry
【24h】

Recent DBT-BIRAC intiatives postured to boost India's biotech industry

机译:DBT-BIRAC最近的举措旨在推动印度生物技术产业发展

获取原文
获取原文并翻译 | 示例
           

摘要

Representatives from the Department of Biotechnology and the Biotechnology Industry Research Assistance Council share their views on government intiatives and growth of the sector.It is widely recognized that biotechnology has a wealth of potential applications and, with that, much economic promise. Today, the Indian biotech industry is thought to be worth around $4bn (Rs. 20,000 crores) with more than 700 companies currently operating in the sector. Progress in the field has opened up unprecedented opportunities for bio-entrepreneurship via the development and commercialization of innovative research.The biotech industry in India is forecast to generate revenues of about $11.6bn by the year 2017. This growth is expected to be driven by increasing investment from foreign companies, more R&D and infrastructure investments from private and public sectors, the emerging contract research market, increasing clinical capabilities in drug discovery, green technology and more opportunities for enhancing manufacturing capacity in the country.
机译:生物技术部和生物技术产业研究援助理事会的代表就政府倡议和该领域的发展分享了他们的观点。众所周知,生物技术具有许多潜在的应用前景,并且具有巨大的经济前景。如今,据认为印度生物技术产业的价值约为40亿美元(200亿卢比),目前有700多家公司在该领域开展业务。该领域的进展通过创新研究的开发和商业化为生物创业开辟了前所未有的机遇。印度的生物技术产业预计到2017年将产生约116亿美元的收入。这种增长预计将由增长推动来自外国公司的投资,来自私营和公共部门的更多R&D和基础设施投资,新兴的合同研究市场,不断增强的药物开发临床能力,绿色技术,以及在该国增强生产能力的更多机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号